Melanocortin-4 receptor agonists for the treatment of obesity

Current Topics in Medicinal Chemistry

Volumn 7, Issue 11, 2007, Pages 1121-1130

  Emmerson, Paul J ^a   Fisher, Matthew J ^a   Yan, Liang Zeng ^a   Mayer, John P ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Active melanocortin peptides corticotrophin; Aplha msh; Mc4r deficient mice; Melanocortin 3 receptor; Shu9119

Indexed keywords

ACETYLSERYLTYROSYLSERYLNORLEUCYLGLUTAMYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHANYLGLYCYLLYSYLPROLYLVALYLAMIDE; AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; BETA INTERMEDIN; CORTICOTROPIN; GAMMA INTERMEDIN; HEXAPEPTIDE; HORMONE RECEPTOR AFFECTING AGENT; HORMONE RECEPTOR STIMULATING AGENT; LIGAND; MB 243; MELANOCORTIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN 5 RECEPTOR; MELANOTAN II; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NONAPEPTIDE; PENTAPEPTIDE; PEPTIDE; POLYPEPTIDE; RO 27 3225; RO 28 0956; RY 764; TETRAHYDROISOQUINOLINE; UNCLASSIFIED DRUG;

BODY WEIGHT; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; FOOD INTAKE; GENE DELETION; HOMEOSTASIS; HUMAN; HYPERPHAGIA; IN VIVO STUDY; NONHUMAN; OBESITY; REGULATORY MECHANISM; REVIEW; RODENT;

ANIMALS; DRUG DESIGN; HUMANS; MELANOCORTINS; OBESITY; PEPTIDES; RECEPTOR, MELANOCORTIN, TYPE 4; SIGNAL TRANSDUCTION;

EID: 34447272286     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780906636     Document Type: Review

References (97)

1. Yanovski, S. Z.; Yanovski, J. A. Obesity. N. Engl. J. Med., 2002, 346, 591-602.
2. Yach, D.; Stuckler, D.; Brownell, K. D. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat. Med., 2006, 12, 62-66.
3. Polednak, A. P. Trends in incidence rates for obesity-associated cancers in the US. Cancer Detect. Prev., 2003, 27, 415-421.
4. Wyatt, S. B.; Winters, K. P.; Dubbert, P. M. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am. J. Med. Sci., 2006, 331, 166-174.
5. Goldfeder, L. B.; Ren, C. J.; Gill, J. R. Fatal complications of bariatric surgery. Obes. Surg., 2006, 16, 1050-1056.
6. Van Gaal, L. F.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rossner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 2005, 365, 1389-1397.
7. Despres, J. P.; Golay, A.; Sjostrom, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med., 2005, 353, 2121-2134.
8. Wadden, T. A.; Berkowitz, R. L; Womble, L. G.; Sarwer, D. B.; Phelan, S.; Cato, R. K.; Hesson, L. A.; Osei, S. Y.; Kaplan, R.; Stumkard, A. J. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med., 2005, 353, 2111-2120.
9. Yanovski, S. Z. Pharmacotherapy for obesity-promise and uncertainty. N. Engl. J. Med., 2005, 353, 2187-2189.
10. Goodfellow, V. S.; Saunders, J. The melanocortin system and its role in obesity and cachexia. Curr. Top. Med. Chem., 2003, 3, 855-883.
11. Lerner, A. B. The discovery of the melanotropins. A history of pituitary endocrinology. Ann. N. Y. Acad. Sci., 1993, 680, 1-12.
12. Mountjoy, K. G.; Robbins, L. S.; Mortrud, M. T.; Cone, R. D. The cloning of a family of genes that encode the melanocortin receptors. Science, 1992, 257, 1248-1251.
13. Bultman, S. J.; Michaud, E. J.; Woychik, R. P. Molecular characterization of the mouse agouti locus. Cell, 1992, 71, 1195-1204.
14. Garren, L. D. The mechanism of action of adrenocorticotropic hormone. Vitam. Horm., 1968, 26, 119-145.
15. Adan, R. A.; Oosterom, J.; Toonen, R. F.; Kraan, M. V.; Burbach, J. P.; Gispen, W. H. Molecular pharmacology of neural melanocortin receptors. Receptors Channels, 1997, 5, 215-223.
16. Ollmann, M. M.; Wilson, B. D.; Yang, Y. K.; Kerns, J. A.; Chen, Y.; Gantz, I.; Barsh, G. S. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science, 1997, 278, 135-138.
17. Gantz, I.; Konda, Y.; Tashiro, T.; Shimoto, Y.; Miwa, H.; Munzert, G.; Watson, S. J.; DelValle, J.; Yamada, T. Molecular cloning of a novel melanocortin receptor. J. Biol. Chem., 1993, 268, 8246-8250.
18. Chhajlani, V.; Muceniece, R.; Wikberg, J. E. Molecular cloning of a novel human melanocortin receptor. Biochem. Biophys. Res. Commun., 1993, 195, 866-873.
19. Gantz, I.; Miwa, H.; Konda, Y.; Shimoto, Y.; Tashiro, T.; Watson, S. J.; DelValle, J.; Yamada, T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J. Biol. Chem., 1993, 268, 15174-15179.
20. Roselli-Rehfuss, L.; Mountjoy, K. G.; Robbins, L. S.; Mortrud, M. T.; Low, M. J.; Tatro, J. B.; Entwistle, M. L.; Simerly, R. B.; Cone, R. D. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc. Natl. Acad. Sci. USA, 1993, 90, 8856-8860.
21. Nakanishi, S.; Inoue, A.; Kita, T.; Nakamura, M.; Chang, A. C.; Cohen, S. N.; Numa, S. Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature, 1979, 278, 423-427.
22. Cone, R. D., The Melanocortin Receptors. Humana Press: Totowa,. New Jersey, 2000.
23. Ferrari, W. Behavioural changes in animals after intracisternal injection with adrenocorticotrophic hormone and melanocyte-stimulatmg hormone. Nature, 1958, 181, 925-926.
24. Ferrari, W.; Gessa, G. L.; Vargiu, L. Behavioral effects induced by intracisternally injected ACTH and MSH. Ann. N. Y. Acad. Sci., 1963, 104, 330-345.
25. Moyer, K. E. Effect of ACTH on open-field behavior, avoidance, startle, and food and water consumption. J. Genet. Psychol., 1966, 108, 297-302.
26. Sandman, C. A.; Kastin, A. J.; Schally, A. V. Melanocyte-stimulating hormone and learned appetitive behavior. Experientia, 1969, 25, 1001-1002.
27. Panskepp, J.; Reilly, P.; Bishop, P.; Mecker, R. B.; Vilberg, T. R.; Kastin, A. J. Effects of alpha-MSH on motivation, vigilance and brain respiration. Pharmacol. Biochem. Behav., 1976, 5, 59-64.
28. Vergoni, A. V.; Poggioli, R.; Bertolini, A. Corticotropin inhibits food intake in rats. Neuropeptides, 1986, 7, 153-158.
29. Poggioli, R.; Vergoni, A. V.; Bertolini, A. ACTH-(1-24) and alpha-MSH antagonize feeding behavior stimulated by kappa opiate agonists. Peptides, 1986, 7, 843-848.
30. Tsujii, S.; Bray, G. A. Acetylation alters the feeding response to MSH and beta-endorphin. Brain Res. Bull., 1989, 23, 165-169.
31. Vergoni, A. V.; Poggioli, R.; Marrama, D.; Bertolini, A. Inhibition of feeding by ACTH-(1-24): behavioral and pharmacological aspects. Eur. J. Pharmacol., 1990, 179, 347-355.
32. Sawyer, T. K.; Sanfilippo, P. J.; Hruby, V. J.; Engel, M. H.; Heward, C. B.; Burnett, J. B.; Hadley, M. E. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. USA, 1980, 77, 5754-5758.
33. Hruby, V. J.; Sharma, S. D.; Toth, K.; Jaw, J. Y.; al-Obeidi, F.; Sawyer, T. K.; Hadley, M. E. Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann. N. Y. Acad. Sci., 1993, 680, 51-63.
34. Al-Obeidi, F.; Castrucci, A. M.; Hadley, M. E.; Hruby, V. J. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J. Med. Chem., 1989, 32, 2555-2561.
35. Hruby, V. J.; Lu, D.; Sharma, S. D.; Castrucci, A. L.; Kesterson, R. A.; al-Obeidi, F. A.; Hadley, M. E.; Cone, R. D. Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10]alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem., 1995, 38, 3454-3461.
36. Fan, W.; Boston, B. A.; Kesterson, R. A.; Hruby, V. J.; Cone, R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature, 1997, 385, 165-168.
37. Huszar, D.; Lynch, C. A.; Fairchild-Huntress, V.; Dunmore, J. H.; Fang, Q.; Berkemeier, L. R.; Gu, W.; Kesterson, R. A.; Boston, B. A.; Cone, R. D.; Smith, F. J.; Campfield, L. A.; Burn, P.; Lee, F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell, 1997, 88, 131-141.
38. Marsh, D. J.; Hollopeter, G.; Huszar, D.; Laufer, R.; Yagaloff, K. A.; Fisher, S. L.; Burn, P.; Palmiter, R. D. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat. Genet., 1999, 21, 119-122.
39. Cuenot L. Les Races Pores et Leurs Combinalaisons Chez Les Souris. Arch. Zool. Exp. Gen., 1995, 3, 123-132.
40. Castle WE Size Genes of Mice. Genetics, 1942, 28, 69-72.
41. Lu, D.; Willard, D.; Patel, I. R.; Kadwell, S.; Overton, L.; Kost, T.; Luther, M.; Chen, W.; Woychik, R. P.; Wilkison, W. O.; Cone, R.D. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature, 1994, 371, 799-802.
42. Arasasingham, P. N.; Fotsch, C.; Ouyang, X.; Norman, M. H.; Kelly, M. G.; Stark, K. L.; Karbon, B.; Hale, C.; Baumgartner, J. W.; Zambrano, M.; Cheetham, J.; Tamayo, N. A. Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: antagonists for the AGRP/ melanocortin receptor binding. J. Med. Chem., 2003, 46, 9-11.
43. Koegler, F. H.; Grove, K. L.; Schiffmacher, A.; Smith, M. S.; Cameron, J. L. Central melanocortin receptors mediate changes in food intake in the rhesus macaque. Endocrinology, 2001, 142, 2586-2592.
44. Krude, H.; Biebermann, H.; Luck, W.; Horn, R.; Brabant, G.; Gruters, A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat. Genet., 1998, 19, 155-157.
45. Branson, R.; Potoczna, N.; Kral, J. G.; Lentes, K. U.; Hoehe, M. R.; Horber, F. F. Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N. Engl. J. Med., 2003, 348, 1096-1103.
46. Farooqi, I. S.; Keogh, J. M.; Yeo, G. S.; Lank, E. J.; Cheetham, T.; O'Rahilly, S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N. Engl. J. Med., 2003, 348, 1085-1095.
47. Fehm, H. L.; Smolnik R.; Kern, W.; McGregor, G. P.; Bickel, U.; Born, J. The melanocortin melanocyte-stimulating hormone/ adrenocorticotropin(4-10) decreases body fat in humans. J. Clin. Endocrinol. Metab., 2001, 86, 1144-1148.
48. Hallschmid, M.; Smolnik, R.; McGregor, G.; Born, J.; Fehm, H. L. Overweight humans are resistant to the weight-reducing effects of melanocortin4-10. J. Clin. Endocrinol. Metab., 2006, 91, 522-525.
49. Krude, H.; Biebermann, H.; Schnabel, D.; Tansek, M. Z.; Theunissen, P.; Mullis, P. E.; Gruters, A. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J. Clin. Endocrinol. Metab., 2003, 88, 4633-4640.
50. Schioth, H. B.; Muceniece, R.; Wikberg, J. E. Characterisation of the melanocortin 4 receptor by radioligand binding. Pharmacol. Toxicol., 1996, 79, 161-165.
51. Born, J.; Lange, T.; Kern, W.; McGregor, G. P.; Bickel, U.; Fehm, H. L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci., 2002, 5, 514-516.
52. Yaswen, L.; Diehl, N.; Brennan, M. B.; Hochgeschwender, U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat. Med., 1999, 5, 1066-1070.
53. Bluher, S.; Ziotopoulou, M.; Bullen, J. W., Jr.; Moschos, S. J.; Ungsunan, L.; Kokkotau, E.; Maratos-Flier, E.; Mantzoros, C. S. Responsiveness to peripherally administered melanocortins in lean and obese mice. Diabetes, 2004, 53, 82-90.
54. Pierroz, D. D.; Ziotopoulou, M.; Ungsunan, L.; Moschos, S.; Flier, J. S.; Mantzoros, C. S. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes, 2002, 51, 1337-1345.
55. Trivedi, P.; Jiang, M.; Tamvakopoulos, C. C.; Shen, X.; Yu, H.; Mock S.; Fenyk-Melody, J.; Van der Ploeg, L. H.; Guan, X. M. Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MTII in rats. Brain Res., 2003, 977, 221-230.
56. Wessells, H.; Hruby, V. J.; Hackett, J.; Han, G.; Balse-Srinivasan, P.; Vanderah, T. W. Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience, 2003, 118, 755-762.
57. Wessells, H.; Levine, N.; Hadley, M. E.; Dorr, R.; Hruby, V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int. J. Impot. Res., 2000, 12 (Suppl 4), S74-79.
58. Benoit, S. C.; Schwartz, M. W.; Lachey, J. L.; Hagan, M. M.; Rushing, P. A.; Blake, K. A.; Yagaloff, K. A.; Kurylko, G.; Franco, L.; Danhoo, W.; Seeley, R. J. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive, consequences. J. Neurosci., 2000, 20, 3442-3448.
59. Thiele, T. E.; van Dijk, G.; Yagaloff K. A.; Fisher, S. L.; Schwartz, M.; Burn, P.; Seeley, R. J. Central infusion of melanocortin agonist MTII in rats: assessment of c-Fos expression and taste aversion. Am. J. Physiol., 1998, 274, R248-254.
60. Cheung, A. W.; Danho, W.; Swistok, J.; Qi, L.; Kurylko, G.; Franco, L.; Yagaloff, K.; Chen, L. Structure-activity relationship of linear peptide Bu- His-DPhe-Arg-Trp-Gly-NH(2) at the human melanocortin-1 and -4 receptors: arginine substitution. Bioorg. Med. Chem. Lett., 2002, 12 2407-2410.
61. Danho, W.; Swistok, J.; Cheung, A. W.; Kurylko, G.; Franco, L.; Chu, X. J.; Chen, L.; Yagaloff K. Structure-activity relationship of linear peptide Bu- His6-DPhe7-Arg8-Trp9-Gly10-NH2 at the human melanocortin-1 and -4 receptors: DPhe7 and Trp9 substitution. Biborg. Med Chem. Lett., 2003, 13, 649-652.
62. Holder, J. R.; Xiang, Z.; Bauzo, R. M.; Haskell-Luevano, C. Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors. Part 3: modifications at the Arg position. Peptides, 2003, 24, 73-82.
63. Holder, J. R.; Xiang, Z.; Bauzo, R. M.; Haskell-Luevano, C. Structure-activity relationships of the melanocortin tetrapeptide Ac-His-D-Phe-Arg-Trp-NH2 at the mouse melanocortin receptors. 4. Modifications at the Trp position. J. Med. Chem., 2002, 45, 5736-5744.
64. Holder, J. R.; Bauzo, R. M.; Xiang, Z.; Haskell-Luevano, C. Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors: part 2 modifications at the Phe position. J. Med. Chem., 2002, 45, 3073-3081.
65. Nijenhuis, W. A.; Kruijtzer, J. A.; Wanders, N.; Vrinten, D. H.; Garner, K. M.; Schaaper, W. M.; Meloen, R. H.; Gispen, W. H.; Liskamp, R. M.; Adan, R. A. Discovery and in vivo evaluation of new melanocortin-4 receptor-selective peptides. Peptides, 2003, 24, 271-280.
66. Cheung, A. W.; Danho, W.; Swistok, J.; Qi, L.; Kurylko, G.; Rowan, K.; Yeon, M.; Franco, L.; Chu, X. J.; Chen, L.; Yagaloff, K. Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH(2) at the human melanocortin-1 and -4 receptors: histidine substitution. Bioorg. Med. Chen. Lett., 2003, 13, 133-137.
67. Chu, X. J.; Bartkovitz, D.; Danho, W.; Swistok, J.; Cheung, A. W.; Kurylko, G.; Rowan, K.; Yeon, M.; Franco, L.; Qi, L.; Chen, L.; Yagaloff, K. Discovery of 1-amino-4-phenylcyclohexane-1-carboxylic acid and its influence on agonist selectivity between human melanocortin-4 and -1 receptors in linear pentapeptides. Bioorg. Med. Chem. Lett., 2005, 15, 4910-4914.
68. Holder, J. R.; Bauzo, R. M.; Xiang, Z.; Haskell-Luevano, C. Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors. 1. Modifications at the His position. J. Med Chem., 2002, 45, 2801-2810.
69. Ye, Z.; MacNeil, T.; Weinberg, D. H.; Kalyani, R. N.; Tang, R.; Strack, A. M.; Murphy, B. A.; Mosley, R. T.; Euan MacIntyre D.; Van der Ploeg, L. H.; Patchett, A. A.; Wyvratt, M. J.; Nargund, R. P. Structure-activity relationship of linear tetrapeptides Tic-DPhe-Arg-Trp-NH2 at the human melanocortin-4 receptor and effects on feeding behaviors in rat. Peptides, 2005, 26, 2017-2025.
70. Koikov, L. N.; Ebetino, F. H.; Hayes, J. C.; Cross-Doersen, D.; Knittel, J. J. End-capping of the modified melanocortin tetrapeptide (p-Cl)Phe-D-Phe-Arg-Trp-NH2 as a route to hMC4R agonists. Bioorg. Med. Chem. Lett., 2004, 14, 4839-4842.
71. Ebetino, F. H.; Mazur A. W.; Hayes, J. C.; Wang, F.; Solinsky, M. G.; Colson, A.; Q. L. Melanocortin Receptor Ligands. WO 02/26774 A2, 2002.
72. Yan, L. Z.; Flora, D.; Edwards, P.; Smiley, D. L.; Emmerson, P. J.; Hsiung, H. M.; Gadski, R.; Hertel, J.; Heiman, M. L.; Husain, S.; O'Brien, T. P.; Kahl, S. D.; Zhang, L.; DiMarchi, R. D.; Mayer, J. P. Potent and selective MC-4 receptor agonists based on a novel disulfide scaffold. Bioorg. Med. Chem. Lett., 2005, 15, 4611-4614.
73. Danho W.; Swistok J.; Cheung A.; Chu X. J.; Wang Y.; Chen L.; Bartkovitz D.; Gore V.; Qi L.; Fry D.; Greeley D.; Sun H.; Guenot J.; Franco L.; Kurylko G.; Rumennik L.; K., Y. In Highly Selective Cyclic Peptides for Human Melanocortin-4 Receptor (MC-4 R): Design, Synthesis, Bioactive Conformation, and Pharmacological Evaluation as an Anti-Obesity Agent, Proceedings of the Second International and the Seventeenth American Peptide Symposium, 2001; pp. 701.
74. Cheung, A. W.; Danho, W.; Swistok, J.; Qi, L.; Kurylko, G.; Rowan, K.; Yeon, M.; Franco, L.; Chu, X. J.; Chen, L.; Yagaloff, K. Structure-activity relationship of cyclic peptide penta-c[Asp-His(6)-DPhe(7)-Arg(8)-Trp(9)-Lys]-NH(2) at the human melanocortin-1 and -4 receptors: His(6) substitution. Bioorg. Med. Chem Lett., 2003, 13, 1307-1311.
75. Bednarek, M. A.; MacNeil, T.; Tang, R.; Kalyani, R. N.; Van der Ploeg, L. H.; Weinberg, D. H. Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. Biochem. Biophys. Res. Commun., 2001, 286, 641-645.
76. Kavarana, M. J.; Trivedi, D.; Cai, M.; Ying, J.; Hammer, M.; Cabello, C.; Grieco, P.; Han, G.; Hruby, V. J. Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J. Med Chem 2002, 45, 2644-2650.
77. Mazur A. W.; Wang F.; Sheldon R. J.; Ebetino, F. H. Melanocortin Receptor Ligands. WO 00/58361, 2000.
78. Hsiung, H. M.; Hertel, J.; Zhang, X. Y.; Smith, D. P.; Smiley, D. L.; Heiman, M. L.; Yang, D. D.; Husain, S.; Mayer, J. P.; Zhang, L.; Mo, H.; Yan, L. Z. A novel and selective beta-melanocyte-stimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese rats. Endocrinology, 2005, 146, 5257-5266.
79. Emmerson P. J.; Thielen S.; Chesterfield M. M.; Eastwood B.; Patel N.; Husain S.; O'Brien T. P.; Kahl S. D.; Yan L. Z.; Mayer J. P. In The behavioral effects of peripherally administered melanocortin peptides are mediated through activation of the MC4 receptor in mice, Society for Neuroscience Abstracts, 2005; Abstract Viewer/Itinerary Planner: 2005; pp. 313.315.
80. Mayer, J. P.; Hsiung, H. M.; Flora, D. B.; Edwards, P.; Smith, D. P.; Zhang, X. Y.; Gadski, R. A.; Heiman, M. L.; Hertel, J. L.; Emmerson, P. J.; Husain, S.; O'Brien T, P.; Kahl, S. D.; Smiley, D. L.; Zhang, L.; DiMarchi, R. D.; Yan, L. Z. Discovery of a beta-MSH-derived MC-4R selective agonist. J. Med. Chem., 2005, 48, 3095-3098.
81. Todorovic, A.; Haskell-Luevano, C. A review of melanocortin receptor small molecule ligands. Peptides, 2005, 26, 2026-2036.
82. Bednarek M. A.; Fong T. M. Ligands of the melanocortin receptors, 2002-2003 update. Expert Opin. Therapeut. Pat., 2004, 14, 327-336.
83. Sebhat I. K.; Martin, W. J.; Ye, Z.; Barakat, K.; Mosley, R. T.; Johnston, D. B.; Bakshi, R.; Palucki, B.; Weinberg, D. H.; MacNeil, T.; Kalyani, R. N.; Tang, R.; Stearns, R. A.; Miller, R. R.; Tamvakopoulos, C.; Strack, A. M.; McGowan, E.; Cashen, D. E.; Drisko, J. E.; Hom, G. J.; Howard, A. D.; MacIntyre, D. E.; van der Ploeg, L. H.; Patchett; A. A.; Nargund, R. P. Design and pharmacology of N-[(3R)-1,2,3,4-tetrohydroisoquinolinium- 3- ylcarbonyl]-(1R)-1-(4-cholorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1- ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent selective, melanocortin subtype-4 receptor agonist. J. Med. Chem., 2002, 45, 4589-4593.
84. Dyck, B.; Parker, J.; Phillips, T.; Carter, L.; Murphy, B.; Summers, R.; Hermann, J.; Baker, T.; Cismowski, M.; Saunders, J.; Goodfellow, V. Aryl piperazine melanocortin MC4 receptor agonists. Bioorg. Med. Chem. Lett., 2003, 13, 3793-3796.
85. Cepoi, D.; Phillips, T.; Cismowski, M.; Goodfellow, V. S.; Ling, N.; Cone, R. D.; Fan, W. Assessment of a small molecule melanocortin-4 receptor-specific agonist on energy homeostasis. Brain Res., 2004, 1000, 64-71.
86. Nordheim, U.; Nicholson, J. R.; Dokladny, K.; Dunant, P.; Hofbauer, K. G. Cardiovascular responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats. Peptides, 2006, 27, 438-443.
87. Richardson, T. I.; Ornstein, P. L.; Briner, K.; Fisher, M. J.; Backer, R. T.; Biggers, C. K.; Clay, M. P.; Emmerson, P. J.; Hertel, L. W.; Hsiung, H. M.; Husain, S.; Kahl, S. D.; Lee, J. A.; Lindstrom, T. D.; Martinelli, M. J.; Mayer, J. P.; Mullaney, J. T.; O'Brien, T. P.; Pawlak, J. M.; Revell, K. D.; Shah, J.; Zgombick, J. M.; Herr, R. J.; Melekhov, A.; Sampson, P. B.; King, C. H. Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor. J. Med. Chem., 2004, 47, 744-755.
88. Fotsch, C., H.; Arasasingham, P.; Bo, Y.; Chen, N.; Goldberg, M., H.; Han, N.; Hsieh, F.-Y.; Kelly, M., G.; Liu, Q.; Norman, M., H.; Smith, D., M.; Stec, M.; Tamayo, N.; Xi, N.; Xu, S. Substituted piperazines as modulators of the melanocortin receptor. WO 03/009850, 2003.
89. Fotsch, C., H.; Croghan, M.; Doherty, E., M.; Kelly, M., G.; Norman, M., H.; Smith, D., M.; Tamayo, N.; Xi, N.; Xu, S. Substituted piperidines as modulators of the melanocortin receptor. WO 03/009847, 2003.
90. Fotsch, C.; Han, N.; Arasasingham, P.; Bo, Y.; Carmouche, M.; Chen, N.; Davis, J.; Goldberg, M. H.; Hale, C.; Hsieh, F. Y.; Kelly, M. G.; Liu, Q.; Norman, M. H.; Smith, D. M.; Stec, M.; Tamayo, N.; Xi, N.; Xu, S.; Bannon, A. W.; Baumgartner, J. W. Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides. Bioorg. Med. Chem. Lett., 2005, 15, 1623-1627.
91. Palucki, B. L.; Park, M. K.; Nargund, R. P.; Ye, Z.; Sebhat, I. K.; Pollard, P. G.; Kalyani, R. N.; Tang, R.; Macneil, T.; Weinberg, D. H.; Vongs, A.; Rosenblum, C. I.; Doss, G. A.; Miller, R. R.; Stearns, R. A.; Peng, Q.; Tamvakopoulos, C.; McGowan, E.; Martin, W. J.; Metzger, J. M.; Shepherd, C. A.; Strack, A. M.; Macintyre, D. E.; Van der Ploeg, L. H.; Patchett; A. A. Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl4- (1,1-dimethylethyl)amino] carbonyl]-1-pipe ridinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl- 2-piperazinecarbo xamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett., 2005, 15, 171-175.
92. Ye, Z.; Guo, L.; Barakat, K. J.; Pollard, P. G.; Palucki, B. L.; Sebhat, I. K.; Bakshi, R. K.; Tang, R.; Kalyani, R. N.; Vongs, A.; Chen, A. S.; Chen, H. Y.; Rosenblum, C. I.; MacNeil, T.; Weinberg, D. H.; Peng, Q.; Tamvakopoulos, C.; Miller, R. R.; Stearns, R. A.; Cashen, D. E.; Martin, W. J.; Metzger, J. M.; Strack, A. M.; MacIntyre, D. E.; Van der Ploeg, L. H.; Patchett; A. A.; Wyvratt, M. J.; Nargund, R. P. Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4- (1,1-dimethylethyl) amino] carbonyl]- 1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2- azabicycl o[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist Bioorg. Med. Chen Lett., 2005, 15, 3501-3505.
93. Sharma, S., D.; Shi, Y.-Q.; Rajpurohit, R.; Wu, Z.; Purma, P.; Shadiack, A., M.; Burris, K., D. Melanocortin receptor-specific compounds. US 2004/ 0224957, 2004.
94. Boyce, R., S.; Aurrecoehea, N.; Chu, D.; Smith, A.; Conlee, C., R.; Thompson, B., D.; De Armas Kuntz, J.; Musso, D., L.; Barvian, K., K.; Thomson, S., A.; Swain, W., R.; Du, K., S.; Chauder, B., A.; Speake, J., D.; Bishop, M., J. Guanidino-substituted quinazoline compounds as MC4-R agonists. WO 2004/112793, 2004.
95. Szewczyk, J., R.; Speake, J., D.; Sammond, D., M.; Sherrill, R., G. Novel Diazepine Compounds as Ligands of the Melanocortin 1 and/or 4 Receptors. WO 2005/118573, 2005.
96. Pan, K.; Scott, M. K.; Lee, D. H.; Fitzpatrick, L. J.; Crooke, J. J.; Rivero, R. A.; Rosenthal. D. I.; Vaidya, A. H.; Zhao, B.; Reitz, A. B. 2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats. Bioorg Med Chem 2003, 11, 185-192.
97. Neel, L V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 1962. Bull World Health Organ, 1999, 77, 694-703; discussion 692-693.